A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
ConclusionsThese findings confirm the viability of napabucasin plus sorafenib treatment, and there were no safety or tolerability concerns in Japanese patients with unresectable HCC.Clinical Trial RegistrationClinicalTrials.gov identifier NCT02358395, registered on 9 February 2015.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Drugs & Pharmacology | Hepatocellular Carcinoma | Japan Health | Liver Cancer | Study | Toxicology